#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	Early	_
1-2	6-14	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-3	15-18	Use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-4	19-22	and	_
1-5	23-37	Neurocognitive	_
1-6	38-42	Risk	_
1-7	43-44	:	_
1-8	45-46	A	_
1-9	47-58	Prospective	_
1-10	59-69	Functional	_
1-11	70-82	Neuroimaging	_
1-12	83-88	Study	_
1-13	89-99	BACKGROUND	_
1-14	100-101	:	_
1-15	102-115	Retrospective	_
1-16	116-128	neuroimaging	_
1-17	129-136	studies	_
1-18	137-141	have	_
1-19	142-151	suggested	_
1-20	152-154	an	_
1-21	155-166	association	_
1-22	167-174	between	_
1-23	175-180	early	_
1-24	181-189	cannabis	_
1-25	190-195	onset	_
1-26	196-199	and	_
1-27	200-205	later	_
1-28	206-220	neurocognitive	_
1-29	221-231	impairment	_
1-30	232-233	.	_

2-1	234-241	However	_
2-2	242-243	,	_
2-3	244-249	these	_
2-4	250-257	studies	_
2-5	258-262	have	_
2-6	263-267	been	_
2-7	268-275	limited	_
2-8	276-278	in	_
2-9	279-284	their	_
2-10	285-292	ability	_
2-11	293-295	to	_
2-12	296-307	distinguish	_
2-13	308-317	substance	_
2-14	318-321	use	_
2-15	322-326	risk	_
2-16	327-334	factors	_
2-17	335-339	from	_
2-18	340-356	cannabis-induced	_
2-19	357-364	effects	_
2-20	365-367	on	_
2-21	368-382	neurocognition	_
2-22	383-384	.	_

3-1	385-387	We	_
3-2	388-392	used	_
3-3	393-394	a	_
3-4	395-406	prospective	_
3-5	407-413	cohort	_
3-6	414-420	design	_
3-7	421-423	to	_
3-8	424-428	test	_
3-9	429-436	whether	_
3-10	437-451	neurocognitive	_
3-11	452-463	differences	_
3-12	464-472	preceded	_
3-13	473-481	cannabis	_
3-14	482-487	onset	_
3-15	488-489	(	_
3-16	490-499	substance	_
3-17	500-503	use	_
3-18	504-508	risk	_
3-19	509-514	model	_
3-20	515-516	)	_
3-21	517-520	and	_
3-22	521-523	if	_
3-23	524-529	early	_
3-24	530-538	cannabis	_
3-25	539-542	use	_
3-26	543-546	was	_
3-27	547-557	associated	_
3-28	558-562	with	_
3-29	563-569	poorer	_
3-30	570-584	neurocognitive	_
3-31	585-596	development	_
3-32	597-598	(	_
3-33	599-607	cannabis	_
3-34	608-616	exposure	_
3-35	617-622	model	_
3-36	623-624	)	_
3-37	625-626	.	_

4-1	627-634	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
4-2	635-636	:	_
4-3	637-649	Participants	_
4-4	650-651	(	_
4-5	652-653	N	_
4-6	654-655	=	_
4-7	656-658	85	_
4-8	659-660	)	_
4-9	661-670	completed	_
4-10	671-672	a	_
4-11	673-685	visuospatial	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
4-12	686-693	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
4-13	694-700	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
4-14	701-705	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
4-15	706-712	during	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
4-16	713-723	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-17	724-732	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-18	733-742	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-19	743-750	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-20	751-754	and	_
4-21	755-763	multiple	_
4-22	764-773	cognitive	_
4-23	774-785	assessments	_
4-24	786-787	(	_
4-25	788-796	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
4-26	797-809	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
4-27	810-815	Scale	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
4-28	816-819	for	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
4-29	820-831	Children-IV	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
4-30	832-833	,	_
4-31	834-843	Cambridge	_
4-32	844-862	Neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
4-33	863-867	Test	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
4-34	868-877	Automated	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
4-35	878-885	Battery	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
4-36	886-887	)	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
4-37	888-890	at	_
4-38	891-893	12	_
4-39	894-899	years	_
4-40	900-902	of	_
4-41	903-906	age	_
4-42	907-908	,	_
4-43	909-915	before	_
4-44	916-919	any	_
4-45	920-928	reported	_
4-46	929-937	cannabis	_
4-47	938-941	use	_
4-48	942-943	(	_
4-49	944-952	baseline	_
4-50	953-954	)	_
4-51	955-956	,	_
4-52	957-960	and	_
4-53	961-963	at	_
4-54	964-966	15	_
4-55	967-972	years	_
4-56	973-975	of	_
4-57	976-979	age	_
4-58	980-981	(	_
4-59	982-991	follow-up	_
4-60	992-993	:	_
4-61	994-995	N	_
4-62	996-997	=	_
4-63	998-1000	85	_
4-64	1001-1010	cognitive	_
4-65	1011-1022	assessments	_
4-66	1023-1024	,	_
4-67	1025-1026	n	_
4-68	1027-1028	=	_
4-69	1029-1031	67	_
4-70	1032-1044	neuroimaging	_
4-71	1045-1046	)	_
4-72	1047-1048	.	_

5-1	1049-1051	By	_
5-2	1052-1061	follow-up	_
5-3	1062-1063	,	_
5-4	1064-1066	22	_
5-5	1067-1079	participants	_
5-6	1080-1088	reported	_
5-7	1089-1094	using	_
5-8	1095-1103	cannabis	_
5-9	1104-1110	and/or	_
5-10	1111-1117	failed	_
5-11	1118-1119	a	_
5-12	1120-1143	Δ9-tetrahydrocannabinol	_
5-13	1144-1149	urine	_
5-14	1150-1156	screen	_
5-15	1157-1158	(	_
5-16	1159-1164	users	_
5-17	1165-1166	)	_
5-18	1167-1168	.	_

6-1	1169-1176	RESULTS	_
6-2	1177-1178	:	_
6-3	1179-1181	At	_
6-4	1182-1190	baseline	_
6-5	1191-1192	,	_
6-6	1193-1198	group	_
6-7	1199-1210	differences	_
6-8	1211-1220	supported	_
6-9	1221-1222	a	_
6-10	1223-1227	risk	_
6-11	1228-1233	model	_
6-12	1234-1235	.	_

7-1	1236-1241	Those	_
7-2	1242-1245	who	_
7-3	1246-1251	would	_
7-4	1252-1260	initiate	_
7-5	1261-1269	cannabis	_
7-6	1270-1273	use	_
7-7	1274-1276	by	_
7-8	1277-1279	15	_
7-9	1280-1285	years	_
7-10	1286-1288	of	_
7-11	1289-1292	age	_
7-12	1293-1296	had	_
7-13	1297-1307	activation	_
7-14	1308-1319	differences	_
7-15	1320-1322	in	_
7-16	1323-1337	frontoparietal	_
7-17	1338-1339	(	_
7-18	1340-1349	increased	_
7-19	1350-1351	)	_
7-20	1352-1355	and	_
7-21	1356-1362	visual	_
7-22	1363-1374	association	_
7-23	1375-1376	(	_
7-24	1377-1386	decreased	_
7-25	1387-1388	)	_
7-26	1389-1396	regions	_
7-27	1397-1400	and	_
7-28	1401-1407	poorer	_
7-29	1408-1417	executive	_
7-30	1418-1426	planning	_
7-31	1427-1433	scores	_
7-32	1434-1435	(	_
7-33	1436-1445	Stockings	_
7-34	1446-1448	of	_
7-35	1449-1458	Cambridge	_
7-36	1459-1460	)	_
7-37	1461-1469	compared	_
7-38	1470-1474	with	_
7-39	1475-1488	noninitiators	_
7-40	1489-1490	.	_

8-1	1491-1498	Limited	_
8-2	1499-1506	support	_
8-3	1507-1510	was	_
8-4	1511-1516	found	_
8-5	1517-1520	for	_
8-6	1521-1522	a	_
8-7	1523-1531	cannabis	_
8-8	1532-1540	exposure	_
8-9	1541-1546	model	_
8-10	1547-1548	.	_

9-1	1549-1551	At	_
9-2	1552-1561	follow-up	_
9-3	1562-1563	,	_
9-4	1564-1574	activation	_
9-5	1575-1577	in	_
9-6	1578-1581	the	_
9-7	1582-1588	cuneus	_
9-8	1589-1598	displayed	_
9-9	1599-1600	a	_
9-10	1601-1612	significant	_
9-11	1613-1621	cannabis	_
9-12	1622-1635	dose-response	_
9-13	1636-1648	relationship	_
9-14	1649-1650	,	_
9-15	1651-1659	although	_
9-16	1660-1667	neither	_
9-17	1668-1676	cannabis	_
9-18	1677-1681	dose	_
9-19	1682-1685	nor	_
9-20	1686-1692	cuneus	_
9-21	1693-1703	activation	_
9-22	1704-1707	was	_
9-23	1708-1718	associated	_
9-24	1719-1723	with	_
9-25	1724-1733	cognitive	_
9-26	1734-1745	performance	_
9-27	1746-1747	.	_

10-1	1748-1759	CONCLUSIONS	_
10-2	1760-1761	:	_
10-3	1762-1765	The	_
10-4	1766-1775	purported	_
10-5	1776-1790	neurocognitive	_
10-6	1791-1798	effects	_
10-7	1799-1801	of	_
10-8	1802-1807	early	_
10-9	1808-1816	cannabis	_
10-10	1817-1822	onset	_
10-11	1823-1826	may	_
10-12	1827-1830	not	_
10-13	1831-1833	be	_
10-14	1834-1837	due	_
10-15	1838-1840	to	_
10-16	1841-1849	cannabis	_
10-17	1850-1860	initiation	_
10-18	1861-1866	alone	_
10-19	1867-1870	but	_
10-20	1871-1875	also	_
10-21	1876-1882	driven	_
10-22	1883-1885	by	_
10-23	1886-1897	limitations	_
10-24	1898-1900	or	_
10-25	1901-1905	late	_
10-26	1906-1917	development	_
10-27	1918-1920	of	_
10-28	1921-1935	neurocognitive	_
10-29	1936-1943	systems	_
10-30	1944-1954	predictive	_
10-31	1955-1957	of	_
10-32	1958-1967	substance	_
10-33	1968-1971	use	_
10-34	1972-1973	.	_

11-1	1974-1976	In	_
11-2	1977-1985	addition	_
11-3	1986-1987	,	_
11-4	1988-1992	more	_
11-5	1993-2002	prolonged	_
11-6	2003-2011	cannabis	_
11-7	2012-2020	exposure	_
11-8	2021-2024	may	_
11-9	2025-2027	be	_
11-10	2028-2036	required	_
11-11	2037-2039	to	_
11-12	2040-2047	observe	_
11-13	2048-2051	the	_
11-14	2052-2061	cognitive	_
11-15	2062-2069	effects	_
11-16	2070-2072	of	_
11-17	2073-2078	early	_
11-18	2079-2087	cannabis	_
11-19	2088-2093	onset	_
11-20	2094-2095	.	_

12-1	2096-2103	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	2104-2107	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	2108-2117	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	2118-2127	Procedure	_
12-5	2128-2140	Participants	_
12-6	2141-2145	were	_
12-7	2146-2155	recruited	_
12-8	2156-2158	at	_
12-9	2159-2161	12	_
12-10	2162-2167	years	_
12-11	2168-2170	of	_
12-12	2171-2174	age	_
12-13	2175-2176	.	_

13-1	2177-2188	Recruitment	_
13-2	2189-2197	included	_
13-3	2198-2200	an	_
13-4	2201-2208	initial	_
13-5	2209-2217	approach	_
13-6	2218-2222	that	_
13-7	2223-2231	enriched	_
13-8	2232-2241	substance	_
13-9	2242-2245	use	_
13-10	2246-2250	risk	_
13-11	2251-2266	characteristics	_
13-12	2267-2268	(	_
13-13	2269-2277	maternal	_
13-14	2278-2287	substance	_
13-15	2288-2291	use	_
13-16	2292-2295	and	_
13-17	2296-2299	low	_
13-18	2300-2308	maternal	_
13-19	2309-2322	socioeconomic	_
13-20	2323-2329	status	_
13-21	2330-2331	[	_
13-22	2332-2335	SES	_
13-23	2336-2337	]	_
13-24	2338-2340	as	_
13-25	2341-2345	well	_
13-26	2346-2348	as	_
13-27	2349-2360	participant	_
13-28	2361-2371	delinquent	_
13-29	2372-2380	behavior	_
13-30	2381-2382	,	_
13-31	2383-2387	poor	_
13-32	2388-2396	academic	_
13-33	2397-2408	performance	_
13-34	2409-2410	,	_
13-35	2411-2414	and	_
13-36	2415-2419	peer	_
13-37	2420-2429	substance	_
13-38	2430-2433	use	_
13-39	2434-2435	)	_
13-40	2436-2444	followed	_
13-41	2445-2447	by	_
13-42	2448-2449	a	_
13-43	2450-2454	more	_
13-44	2455-2464	inclusive	_
13-45	2465-2474	community	_
13-46	2475-2483	sampling	_
13-47	2484-2492	approach	_
13-48	2493-2494	.	_

14-1	2495-2507	Participants	_
14-2	2508-2509	’	_
14-3	2510-2519	substance	_
14-4	2520-2523	use	_
14-5	2524-2525	,	_
14-6	2526-2539	externalizing	_
14-7	2540-2548	symptoms	_
14-8	2549-2550	,	_
14-9	2551-2554	and	_
14-10	2555-2566	demographic	_
14-11	2567-2571	data	_
14-12	2572-2576	were	_
14-13	2577-2585	assessed	_
14-14	2586-2588	at	_
14-15	2589-2591	12	_
14-16	2592-2593	,	_
14-17	2594-2596	13	_
14-18	2597-2598	,	_
14-19	2599-2601	14	_
14-20	2602-2603	,	_
14-21	2604-2607	and	_
14-22	2608-2610	15	_
14-23	2611-2616	years	_
14-24	2617-2619	of	_
14-25	2620-2623	age	_
14-26	2624-2625	.	_

15-1	2626-2638	Neuroimaging	_
15-2	2639-2642	and	_
15-3	2643-2652	cognitive	_
15-4	2653-2660	testing	_
15-5	2661-2665	were	_
15-6	2666-2675	conducted	_
15-7	2676-2678	at	_
15-8	2679-2681	12	_
15-9	2682-2685	and	_
15-10	2686-2688	15	_
15-11	2689-2694	years	_
15-12	2695-2697	of	_
15-13	2698-2701	age	_
15-14	2702-2703	.	_

16-1	2704-2707	The	_
16-2	2708-2718	University	_
16-3	2719-2721	of	_
16-4	2722-2732	Pittsburgh	_
16-5	2733-2734	’	_
16-6	2735-2736	s	_
16-7	2737-2750	Institutional	_
16-8	2751-2757	Review	_
16-9	2758-2763	Board	_
16-10	2764-2772	approved	_
16-11	2773-2776	the	_
16-12	2777-2782	study	_
16-13	2783-2793	procedures	_
16-14	2794-2795	.	_

17-1	2796-2801	Legal	_
17-2	2802-2811	guardians	_
17-3	2812-2820	provided	_
17-4	2821-2829	informed	_
17-5	2830-2837	consent	_
17-6	2838-2839	,	_
17-7	2840-2843	and	_
17-8	2844-2847	all	_
17-9	2848-2860	participants	_
17-10	2861-2869	provided	_
17-11	2870-2876	assent	_
17-12	2877-2878	.	_

18-1	2879-2891	Participants	_
18-2	2892-2902	Eighty-six	_
18-3	2903-2915	participants	_
18-4	2916-2925	completed	_
18-5	2926-2929	all	_
18-6	2930-2940	diagnostic	_
18-7	2941-2944	and	_
18-8	2945-2954	substance	_
18-9	2955-2958	use	_
18-10	2959-2970	assessments	_
18-11	2971-2972	,	_
18-12	2973-2976	the	_
18-13	2977-2986	cognitive	_
18-14	2987-2994	battery	_
18-15	2995-2997	at	_
18-16	2998-3000	12	_
18-17	3001-3004	and	_
18-18	3005-3007	15	_
18-19	3008-3013	years	_
18-20	3014-3016	of	_
18-21	3017-3020	age	_
18-22	3021-3022	,	_
18-23	3023-3026	and	_
18-24	3027-3031	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
18-25	3032-3034	at	_
18-26	3035-3037	12	_
18-27	3038-3043	years	_
18-28	3044-3046	of	_
18-29	3047-3050	age	_
18-30	3051-3052	(	_
18-31	3053-3061	baseline	_
18-32	3062-3063	)	_
18-33	3064-3065	.	_

19-1	3066-3069	One	_
19-2	3070-3081	participant	_
19-3	3082-3085	was	_
19-4	3086-3093	removed	_
19-5	3094-3098	from	_
19-6	3099-3102	all	_
19-7	3103-3111	analyses	_
19-8	3112-3117	based	_
19-9	3118-3120	on	_
19-10	3121-3129	reported	_
19-11	3130-3138	cannabis	_
19-12	3139-3142	use	_
19-13	3143-3145	at	_
19-14	3146-3154	baseline	_
19-15	3155-3156	,	_
19-16	3157-3166	resulting	_
19-17	3167-3169	in	_
19-18	3170-3171	a	_
19-19	3172-3176	full	_
19-20	3177-3183	sample	_
19-21	3184-3186	of	_
19-22	3187-3188	N	_
19-23	3189-3190	=	_
19-24	3191-3193	85	_
19-25	3194-3195	.	_

20-1	3196-3198	Of	_
20-2	3199-3204	these	_
20-3	3205-3206	,	_
20-4	3207-3209	67	_
20-5	3210-3222	participants	_
20-6	3223-3235	successfully	_
20-7	3236-3245	completed	_
20-8	3246-3250	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
20-9	3251-3262	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
20-10	3263-3265	at	_
20-11	3266-3268	15	_
20-12	3269-3274	years	_
20-13	3275-3277	of	_
20-14	3278-3281	age	_
20-15	3282-3283	(	_
20-16	3284-3293	follow-up	_
20-17	3294-3295	)	_
20-18	3296-3297	.	_

21-1	3298-3305	Reasons	_
21-2	3306-3309	for	_
21-3	3310-3322	unsuccessful	_
21-4	3323-3335	neuroimaging	_
21-5	3336-3345	follow-up	_
21-6	3346-3350	were	_
21-7	3351-3357	braces	_
21-8	3358-3359	(	_
21-9	3360-3361	n	_
21-10	3362-3363	=	_
21-11	3364-3365	8	_
21-12	3366-3367	)	_
21-13	3368-3369	,	_
21-14	3370-3376	opting	_
21-15	3377-3380	out	_
21-16	3381-3382	(	_
21-17	3383-3384	n	_
21-18	3385-3386	=	_
21-19	3387-3388	5	_
21-20	3389-3390	)	_
21-21	3391-3392	,	_
21-22	3393-3399	unable	_
21-23	3400-3402	to	_
21-24	3403-3411	schedule	_
21-25	3412-3413	(	_
21-26	3414-3415	n	_
21-27	3416-3417	=	_
21-28	3418-3419	4	_
21-29	3420-3421	)	_
21-30	3422-3423	,	_
21-31	3424-3427	and	_
21-32	3428-3447	participant-elected	_
21-33	3448-3453	early	_
21-34	3454-3458	scan	_
21-35	3459-3470	termination	_
21-36	3471-3472	(	_
21-37	3473-3474	n	_
21-38	3475-3476	=	_
21-39	3477-3478	1	_
21-40	3479-3480	)	_
21-41	3481-3482	.	_

22-1	3483-3485	At	_
22-2	3486-3494	baseline	_
22-3	3495-3496	,	_
22-4	3497-3506	exclusion	_
22-5	3507-3515	criteria	_
22-6	3516-3524	included	_
22-7	3525-3538	self-reported	_
22-8	3539-3547	cannabis	_
22-9	3548-3551	use	_
22-10	3552-3553	,	_
22-11	3554-3556	IQ	_
22-12	3557-3563	scores	_
22-13	3564-3569	below	_
22-14	3570-3572	80	_
22-15	3573-3574	,	_
22-16	3575-3582	current	_
22-17	3583-3594	psychiatric	_
22-18	3595-3603	disorder	_
22-19	3604-3605	[	_
22-20	3606-3624	Mini-International	_
22-21	3625-3641	Neuropsychiatric	_
22-22	3642-3651	Interview	_
22-23	3652-3653	]	_
22-24	3654-3656	or	_
22-25	3657-3668	psychiatric	_
22-26	3669-3679	medication	_
22-27	3680-3681	,	_
22-28	3682-3690	previous	_
22-29	3691-3695	head	_
22-30	3696-3702	injury	_
22-31	3703-3707	with	_
22-32	3708-3712	loss	_
22-33	3713-3715	of	_
22-34	3716-3729	consciousness	_
22-35	3730-3731	,	_
22-36	3732-3735	and	_
22-37	3736-3739	MRI	_
22-38	3740-3757	contraindications	_
22-39	3758-3759	.	_

23-1	3760-3762	On	_
23-2	3763-3766	the	_
23-3	3767-3770	day	_
23-4	3771-3773	of	_
23-5	3774-3786	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-6	3787-3793	visits	_
23-7	3794-3795	,	_
23-8	3796-3808	participants	_
23-9	3809-3818	completed	_
23-10	3819-3820	a	_
23-11	3821-3830	multidrug	_
23-12	3831-3836	urine	_
23-13	3837-3843	screen	_
23-14	3844-3845	(	_
23-15	3846-3852	Uritox	_
23-16	3853-3860	Medical	_
23-17	3861-3862	,	_
23-18	3863-3869	Toledo	_
23-19	3870-3871	,	_
23-20	3872-3874	OH	_
23-21	3875-3876	;	_
23-22	3877-3880	THC	_
23-23	3881-3890	threshold	_
23-24	3891-3893	50	_
23-25	3894-3899	ng/mL	_
23-26	3900-3901	)	_
23-27	3902-3903	.	_

24-1	3904-3907	All	_
24-2	3908-3920	participants	_
24-3	3921-3927	passed	_
24-4	3928-3931	the	_
24-5	3932-3936	drug	_
24-6	3937-3943	screen	_
24-7	3944-3946	at	_
24-8	3947-3950	the	_
24-9	3951-3959	baseline	_
24-10	3960-3965	visit	_
24-11	3966-3967	.	_

25-1	3968-3971	Two	_
25-2	3972-3984	participants	_
25-3	3985-3991	tested	_
25-4	3992-4000	positive	_
25-5	4001-4004	for	_
25-6	4005-4008	THC	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
25-7	4009-4011	at	_
25-8	4012-4024	neuroimaging	_
25-9	4025-4034	follow-up	_
25-10	4035-4038	and	_
25-11	4039-4043	were	_
25-12	4044-4047	not	_
25-13	4048-4055	scanned	_
25-14	4056-4057	.	_

26-1	4058-4061	One	_
26-2	4062-4073	participant	_
26-3	4074-4077	was	_
26-4	4078-4085	scanned	_
26-5	4086-4091	after	_
26-6	4092-4099	passing	_
26-7	4100-4101	a	_
26-8	4102-4112	subsequent	_
26-9	4113-4118	urine	_
26-10	4119-4125	screen	_
26-11	4126-4127	5	_
26-12	4128-4133	weeks	_
26-13	4134-4139	later	_
26-14	4140-4141	.	_

27-1	4142-4145	The	_
27-2	4146-4151	other	_
27-3	4152-4163	participant	_
27-4	4164-4169	could	_
27-5	4170-4173	not	_
27-6	4174-4176	be	_
27-7	4177-4184	reached	_
27-8	4185-4190	again	_
27-9	4191-4192	.	_

28-1	4193-4196	One	_
28-2	4197-4208	participant	_
28-3	4209-4210	(	_
28-4	4211-4215	user	_
28-5	4216-4217	)	_
28-6	4218-4221	was	_
28-7	4222-4230	excluded	_
28-8	4231-4235	from	_
28-9	4236-4240	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-10	4241-4249	baseline	_
28-11	4250-4258	analysis	_
28-12	4259-4262	for	_
28-13	4263-4273	completing	_
28-14	4274-4278	less	_
28-15	4279-4283	than	_
28-16	4284-4289	three	_
28-17	4290-4292	of	_
28-18	4293-4296	the	_
28-19	4297-4301	four	_
28-20	4302-4309	imaging	_
28-21	4310-4314	runs	_
28-22	4315-4316	.	_

29-1	4317-4319	In	_
29-2	4320-4328	addition	_
29-3	4329-4330	,	_
29-4	4331-4334	one	_
29-5	4335-4346	participant	_
29-6	4347-4348	’	_
29-7	4349-4350	s	_
29-8	4351-4352	(	_
29-9	4353-4360	nonuser	_
29-10	4361-4362	)	_
29-11	4363-4375	neuroimaging	_
29-12	4376-4385	follow-up	_
29-13	4386-4389	was	_
29-14	4390-4393	not	_
29-15	4394-4402	included	_
29-16	4403-4408	owing	_
29-17	4409-4411	to	_
29-18	4412-4413	a	_
29-19	4414-4423	technical	_
29-20	4424-4429	error	_
29-21	4430-4431	.	_

30-1	4432-4435	The	_
30-2	4436-4441	final	_
30-3	4442-4454	neuroimaging	_
30-4	4455-4461	sample	_
30-5	4462-4471	consisted	_
30-6	4472-4474	of	_
30-7	4475-4477	65	_
30-8	4478-4490	participants	_
30-9	4491-4495	with	_
30-10	4496-4508	neuroimaging	_
30-11	4509-4513	data	_
30-12	4514-4516	at	_
30-13	4517-4521	both	_
30-14	4522-4530	baseline	_
30-15	4531-4534	and	_
30-16	4535-4544	follow-up	_
30-17	4545-4546	(	_
30-18	4547-4552	Table	_
30-19	4553-4554	1	_
30-20	4555-4556	)	_
30-21	4557-4558	.	_

31-1	4559-4567	Measures	_
31-2	4568-4576	Cannabis	_
31-3	4577-4580	Use	_
31-4	4581-4582	.	_

32-1	4583-4591	Cannabis	_
32-2	4592-4595	use	_
32-3	4596-4599	was	_
32-4	4600-4608	assessed	_
32-5	4609-4611	at	_
32-6	4612-4614	12	_
32-7	4615-4616	,	_
32-8	4617-4619	13	_
32-9	4620-4621	,	_
32-10	4622-4624	14	_
32-11	4625-4626	,	_
32-12	4627-4630	and	_
32-13	4631-4633	15	_
32-14	4634-4639	years	_
32-15	4640-4642	of	_
32-16	4643-4646	age	_
32-17	4647-4651	with	_
32-18	4652-4661	validated	_
32-19	4662-4673	self-report	_
32-20	4674-4682	measures	_
32-21	4683-4684	[	_
32-22	4685-4686	;	_
32-23	4687-4690	see	_
32-24	4691-4701	Supplement	_
32-25	4702-4703	]	_
32-26	4704-4707	and	_
32-27	4708-4712	kept	_
32-28	4713-4725	confidential	_
32-29	4726-4730	from	_
32-30	4731-4734	the	_
32-31	4735-4747	participants	_
32-32	4748-4749	’	_
32-33	4750-4757	parents	_
32-34	4758-4759	.	_

33-1	4760-4762	At	_
33-2	4763-4771	baseline	_
33-3	4772-4773	(	_
33-4	4774-4776	12	_
33-5	4777-4782	years	_
33-6	4783-4785	of	_
33-7	4786-4789	age	_
33-8	4790-4791	)	_
33-9	4792-4793	,	_
33-10	4794-4796	no	_
33-11	4797-4808	participant	_
33-12	4809-4817	reported	_
33-13	4818-4826	cannabis	_
33-14	4827-4830	use	_
33-15	4831-4832	.	_

34-1	4833-4835	By	_
34-2	4836-4848	neuroimaging	_
34-3	4849-4858	follow-up	_
34-4	4859-4860	(	_
34-5	4861-4863	15	_
34-6	4864-4869	years	_
34-7	4870-4872	of	_
34-8	4873-4876	age	_
34-9	4877-4878	)	_
34-10	4879-4880	,	_
34-11	4881-4883	21	_
34-12	4884-4896	participants	_
34-13	4897-4905	reported	_
34-14	4906-4914	cannabis	_
34-15	4915-4918	use	_
34-16	4919-4925	during	_
34-17	4926-4927	a	_
34-18	4928-4936	previous	_
34-19	4937-4947	assessment	_
34-20	4948-4949	(	_
34-21	4950-4955	13–15	_
34-22	4956-4961	years	_
34-23	4962-4964	of	_
34-24	4965-4968	age	_
34-25	4969-4970	)	_
34-26	4971-4972	.	_

35-1	4973-4976	One	_
35-2	4977-4988	participant	_
35-3	4989-4992	did	_
35-4	4993-4996	not	_
35-5	4997-5003	report	_
35-6	5004-5012	cannabis	_
35-7	5013-5016	use	_
35-8	5017-5020	but	_
35-9	5021-5027	tested	_
35-10	5028-5036	positive	_
35-11	5037-5040	for	_
35-12	5041-5044	THC	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
35-13	5045-5047	at	_
35-14	5048-5060	neuroimaging	_
35-15	5061-5070	follow-up	_
35-16	5071-5072	.	_

36-1	5073-5076	For	_
36-2	5077-5080	the	_
36-3	5081-5088	current	_
36-4	5089-5097	analyses	_
36-5	5098-5099	,	_
36-6	5100-5102	we	_
36-7	5103-5113	classified	_
36-8	5114-5119	these	_
36-9	5120-5132	participants	_
36-10	5133-5135	as	_
36-11	5136-5144	cannabis	_
36-12	5145-5150	users	_
36-13	5151-5152	(	_
36-14	5153-5154	n	_
36-15	5155-5156	=	_
36-16	5157-5159	22	_
36-17	5160-5161	)	_
36-18	5162-5163	.	_

37-1	5164-5167	The	_
37-2	5168-5177	remaining	_
37-3	5178-5190	participants	_
37-4	5191-5195	were	_
37-5	5196-5206	classified	_
37-6	5207-5209	as	_
37-7	5210-5218	nonusers	_
37-8	5219-5220	(	_
37-9	5221-5222	n	_
37-10	5223-5224	=	_
37-11	5225-5227	63	_
37-12	5228-5229	)	_
37-13	5230-5231	.	_

38-1	5232-5236	Four	_
38-2	5237-5249	participants	_
38-3	5250-5253	did	_
38-4	5254-5257	not	_
38-5	5258-5264	report	_
38-6	5265-5273	cannabis	_
38-7	5274-5277	use	_
38-8	5278-5284	during	_
38-9	5285-5293	baseline	_
38-10	5294-5295	,	_
38-11	5296-5299	but	_
38-12	5300-5302	at	_
38-13	5303-5308	later	_
38-14	5309-5320	assessments	_
38-15	5321-5329	reported	_
38-16	5330-5331	a	_
38-17	5332-5340	cannabis	_
38-18	5341-5344	age	_
38-19	5345-5347	of	_
38-20	5348-5353	onset	_
38-21	5354-5358	that	_
38-22	5359-5362	was	_
38-23	5363-5369	during	_
38-24	5370-5372	or	_
38-25	5373-5379	before	_
38-26	5380-5383	the	_
38-27	5384-5392	baseline	_
38-28	5393-5397	year	_
38-29	5398-5399	.	_

39-1	5400-5411	Accordingly	_
39-2	5412-5413	,	_
39-3	5414-5422	baseline	_
39-4	5423-5431	analyses	_
39-5	5432-5436	were	_
39-6	5437-5442	rerun	_
39-7	5443-5452	excluding	_
39-8	5453-5458	these	_
39-9	5459-5471	participants	_
39-10	5472-5473	.	_

40-1	5474-5483	Secondary	_
40-2	5484-5492	analyses	_
40-3	5493-5501	examined	_
40-4	5502-5515	dose-response	_
40-5	5516-5529	relationships	_
40-6	5530-5532	in	_
40-7	5533-5538	users	_
40-8	5539-5543	with	_
40-9	5544-5545	a	_
40-10	5546-5551	total	_
40-11	5552-5560	cannabis	_
40-12	5561-5564	use	_
40-13	5565-5572	measure	_
40-14	5573-5574	(	_
40-15	5575-5578	sum	_
40-16	5579-5581	of	_
40-17	5582-5588	joints	_
40-18	5589-5592	per	_
40-19	5593-5596	day	_
40-20	5597-5601	from	_
40-21	5602-5608	visits	_
40-22	5609-5611	at	_
40-23	5612-5617	13–15	_
40-24	5618-5623	years	_
40-25	5624-5626	of	_
40-26	5627-5630	age	_
40-27	5631-5632	)	_
40-28	5633-5634	.	_

41-1	5635-5637	To	_
41-2	5638-5644	reduce	_
41-3	5645-5648	the	_
41-4	5649-5655	impact	_
41-5	5656-5658	of	_
41-6	5659-5660	a	_
41-7	5661-5664	few	_
41-8	5665-5677	participants	_
41-9	5678-5682	with	_
41-10	5683-5689	higher	_
41-11	5690-5696	levels	_
41-12	5697-5699	of	_
41-13	5700-5703	use	_
41-14	5704-5705	,	_
41-15	5706-5710	this	_
41-16	5711-5718	measure	_
41-17	5719-5722	was	_
41-18	5723-5726	log	_
41-19	5727-5738	transformed	_
41-20	5739-5740	(	_
41-21	5741-5753	Supplemental	_
41-22	5754-5760	Figure	_
41-23	5761-5763	S1	_
41-24	5764-5765	)	_
41-25	5766-5767	.	_

42-1	5768-5781	Externalizing	_
42-2	5782-5790	Symptoms	_
42-3	5791-5792	.	_

43-1	5793-5800	Primary	_
43-2	5801-5811	caregivers	_
43-3	5812-5820	reported	_
43-4	5821-5832	participant	_
43-5	5833-5841	behavior	_
43-6	5842-5844	at	_
43-7	5845-5847	12	_
43-8	5848-5849	,	_
43-9	5850-5852	13	_
43-10	5853-5854	,	_
43-11	5855-5857	14	_
43-12	5858-5859	,	_
43-13	5860-5863	and	_
43-14	5864-5866	15	_
43-15	5867-5872	years	_
43-16	5873-5875	of	_
43-17	5876-5879	age	_
43-18	5880-5885	using	_
43-19	5886-5889	the	_
43-20	5890-5895	Child	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
43-21	5896-5904	Behavior	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
43-22	5905-5914	Checklist	http://maven.renci.org/NeuroBridge/neurobridge#DisruptiveBehaviorDisorder
43-23	5915-5916	.	_

44-1	5917-5926	Covariate	_
44-2	5927-5935	analyses	_
44-3	5936-5940	used	_
44-4	5941-5945	age-	_
44-5	5946-5949	and	_
44-6	5950-5966	gender-corrected	_
44-7	5967-5980	externalizing	_
44-8	5981-5986	scale	_
44-9	5987-5988	t	_
44-10	5989-5995	scores	_
44-11	5996-5997	(	_
44-12	5998-6001	EXT	_
44-13	6002-6003	)	_
44-14	6004-6005	.	_

45-1	6006-6019	Socioeconomic	_
45-2	6020-6026	Status	_
45-3	6027-6028	.	_

46-1	6029-6031	As	_
46-2	6032-6034	in	_
46-3	6035-6040	other	_
46-4	6041-6047	recent	_
46-5	6048-6052	work	_
46-6	6053-6062	examining	_
46-7	6063-6073	adolescent	_
46-8	6074-6082	cannabis	_
46-9	6083-6086	use	_
46-10	6087-6088	,	_
46-11	6089-6091	we	_
46-12	6092-6096	used	_
46-13	6097-6098	a	_
46-14	6099-6108	composite	_
46-15	6109-6117	variable	_
46-16	6118-6120	of	_
46-17	6121-6127	family	_
46-18	6128-6134	income	_
46-19	6135-6138	and	_
46-20	6139-6147	maternal	_
46-21	6148-6157	education	_
46-22	6158-6159	(	_
46-23	6160-6166	family	_
46-24	6167-6182	income–maternal	_
46-25	6183-6192	education	_
46-26	6193-6204	correlation	_
46-27	6205-6206	:	_
46-28	6207-6208	r	_
46-29	6209-6210	=	_
46-30	6211-6215	.496	_
46-31	6216-6217	,	_
46-32	6218-6219	t	_
46-33	6220-6221	=	_
46-34	6222-6226	5.18	_
46-35	6227-6228	,	_
46-36	6229-6230	p	_
46-37	6231-6232	<	_
46-38	6233-6237	.001	_
46-39	6238-6239	)	_
46-40	6240-6242	to	_
46-41	6243-6251	quantify	_
46-42	6252-6255	SES	_
46-43	6256-6259	for	_
46-44	6260-6263	use	_
46-45	6264-6266	as	_
46-46	6267-6268	a	_
46-47	6269-6278	covariate	_
46-48	6279-6282	and	_
46-49	6283-6291	mediator	_
46-50	6292-6293	(	_
46-51	6294-6299	Table	_
46-52	6300-6301	2	_
46-53	6302-6303	)	_
46-54	6304-6305	.	_

47-1	6306-6309	One	_
47-2	6310-6321	participant	_
47-3	6322-6325	did	_
47-4	6326-6329	not	_
47-5	6330-6334	have	_
47-6	6335-6341	family	_
47-7	6342-6348	income	_
47-8	6349-6353	data	_
47-9	6354-6355	.	_

48-1	6356-6359	The	_
48-2	6360-6363	SES	_
48-3	6364-6373	composite	_
48-4	6374-6385	represented	_
48-5	6386-6390	only	_
48-6	6391-6399	maternal	_
48-7	6400-6409	education	_
48-8	6410-6413	for	_
48-9	6414-6418	this	_
48-10	6419-6430	participant	_
48-11	6431-6432	.	_

49-1	6433-6438	Other	_
49-2	6439-6448	Substance	_
49-3	6449-6452	Use	_
49-4	6453-6454	.	_

50-1	6455-6467	Participants	_
50-2	6468-6472	were	_
50-3	6473-6477	also	_
50-4	6478-6483	asked	_
50-5	6484-6489	about	_
50-6	6490-6495	their	_
50-7	6496-6499	use	_
50-8	6500-6502	of	_
50-9	6503-6510	alcohol	_
50-10	6511-6514	and	_
50-11	6515-6522	tobacco	_
50-12	6523-6524	,	_
50-13	6525-6529	with	_
50-14	6530-6539	questions	_
50-15	6540-6548	parallel	_
50-16	6549-6551	to	_
50-17	6552-6555	the	_
50-18	6556-6565	marijuana	_
50-19	6566-6575	questions	_
50-20	6576-6577	.	_

51-1	6578-6580	At	_
51-2	6581-6589	baseline	_
51-3	6590-6591	,	_
51-4	6592-6594	no	_
51-5	6595-6607	participants	_
51-6	6608-6616	reported	_
51-7	6617-6624	alcohol	_
51-8	6625-6628	use	_
51-9	6629-6630	.	_

52-1	6631-6638	However	_
52-2	6639-6640	,	_
52-3	6641-6653	participants	_
52-4	6654-6657	who	_
52-5	6658-6667	initiated	_
52-6	6668-6676	cannabis	_
52-7	6677-6680	use	_
52-8	6681-6683	by	_
52-9	6684-6686	15	_
52-10	6687-6692	years	_
52-11	6693-6695	of	_
52-12	6696-6699	age	_
52-13	6700-6704	were	_
52-14	6705-6709	also	_
52-15	6710-6714	more	_
52-16	6715-6721	likely	_
52-17	6722-6724	to	_
52-18	6725-6731	report	_
52-19	6732-6739	alcohol	_
52-20	6740-6743	use	_
52-21	6744-6745	(	_
52-22	6746-6751	Table	_
52-23	6752-6753	2	_
52-24	6754-6755	)	_
52-25	6756-6757	.	_

53-1	6758-6765	Between	_
53-2	6766-6774	baseline	_
53-3	6775-6778	and	_
53-4	6779-6788	follow-up	_
53-5	6789-6790	,	_
53-6	6791-6794	one	_
53-7	6795-6803	cannabis	_
53-8	6804-6813	initiator	_
53-9	6814-6822	reported	_
53-10	6823-6832	cigarette	_
53-11	6833-6836	use	_
53-12	6837-6840	and	_
53-13	6841-6846	three	_
53-14	6847-6855	reported	_
53-15	6856-6859	use	_
53-16	6860-6862	of	_
53-17	6863-6868	other	_
53-18	6869-6876	illicit	_
53-19	6877-6882	drugs	_
53-20	6883-6884	(	_
53-21	6885-6902	dextromethorphan/	_
53-22	6903-6904	“	_
53-23	6905-6913	triple-c	_
53-24	6914-6915	,	_
53-25	6916-6917	”	_
53-26	6918-6927	mushrooms	_
53-27	6928-6929	,	_
53-28	6930-6933	and	_
53-29	6934-6943	Oxycontin	_
53-30	6944-6945	)	_
53-31	6946-6947	.	_

54-1	6948-6952	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
54-2	6953-6955	WM	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
54-3	6956-6960	Task	_
54-4	6961-6962	.	_

55-1	6963-6965	At	_
55-2	6966-6970	both	_
55-3	6971-6983	neuroimaging	_
55-4	6984-6990	visits	_
55-5	6991-6992	,	_
55-6	6993-7005	participants	_
55-7	7006-7015	performed	_
55-8	7016-7019	the	_
55-9	7020-7024	same	_
55-10	7025-7029	task	_
55-11	7030-7034	used	_
55-12	7035-7037	in	_
55-13	7038-7041	our	_
55-14	7042-7046	work	_
55-15	7047-7056	examining	_
55-16	7057-7065	cannabis	_
55-17	7066-7069	use	_
55-18	7070-7077	history	_
55-19	7078-7080	in	_
55-20	7081-7087	adults	_
55-21	7088-7089	(	_
55-22	7090-7096	Figure	_
55-23	7097-7098	1	_
55-24	7099-7100	)	_
55-25	7101-7102	:	_
55-26	7103-7104	a	_
55-27	7105-7112	spatial	_
55-28	7113-7115	WM	_
55-29	7116-7120	task	_
55-30	7121-7125	with	_
55-31	7126-7127	a	_
55-32	7128-7129	2	_
55-33	7130-7131	(	_
55-34	7132-7136	load	_
55-35	7137-7138	:	_
55-36	7139-7142	one	_
55-37	7143-7145	or	_
55-38	7146-7151	three	_
55-39	7152-7159	spatial	_
55-40	7160-7169	locations	_
55-41	7170-7171	)	_
55-42	7172-7173	×	_
55-43	7174-7175	2	_
55-44	7176-7177	(	_
55-45	7178-7183	delay	_
55-46	7184-7190	length	_
55-47	7191-7192	:	_
55-48	7193-7197	1500	_
55-49	7198-7200	or	_
55-50	7201-7205	6000	_
55-51	7206-7208	ms	_
55-52	7209-7210	)	_
55-53	7211-7212	×	_
55-54	7213-7214	2	_
55-55	7215-7216	(	_
55-56	7217-7220	cue	_
55-57	7221-7229	validity	_
55-58	7230-7231	:	_
55-59	7232-7237	match	_
55-60	7238-7240	or	_
55-61	7241-7249	nonmatch	_
55-62	7250-7257	between	_
55-63	7258-7261	cue	_
55-64	7262-7265	and	_
55-65	7266-7272	target	_
55-66	7273-7274	)	_
55-67	7275-7279	full	_
55-68	7280-7289	factorial	_
55-69	7290-7296	design	_
55-70	7297-7298	.	_

56-1	7299-7302	The	_
56-2	7303-7311	protocol	_
56-3	7312-7315	was	_
56-4	7316-7324	designed	_
56-5	7325-7329	with	_
56-6	7330-7334	four	_
56-7	7335-7347	neuroimaging	_
56-8	7348-7352	runs	_
56-9	7353-7355	of	_
56-10	7356-7358	24	_
56-11	7359-7365	trials	_
56-12	7366-7370	each	_
56-13	7371-7372	.	_

57-1	7373-7375	An	_
57-2	7376-7386	additional	_
57-3	7387-7389	48	_
57-4	7390-7397	partial	_
57-5	7398-7404	trials	_
57-6	7405-7406	(	_
57-7	7407-7417	presenting	_
57-8	7418-7422	only	_
57-9	7423-7426	cue	_
57-10	7427-7429	or	_
57-11	7430-7433	cue	_
57-12	7434-7437	and	_
57-13	7438-7443	delay	_
57-14	7444-7450	phases	_
57-15	7451-7453	of	_
57-16	7454-7457	the	_
57-17	7458-7462	task	_
57-18	7463-7464	)	_
57-19	7465-7466	(	_
57-20	7467-7473	Figure	_
57-21	7474-7475	1	_
57-22	7476-7477	)	_
57-23	7478-7482	were	_
57-24	7483-7487	also	_
57-25	7488-7496	included	_
57-26	7497-7499	to	_
57-27	7500-7508	estimate	_
57-28	7509-7512	the	_
57-29	7513-7524	hemodynamic	_
57-30	7525-7533	response	_
57-31	7534-7536	to	_
57-32	7537-7547	individual	_
57-33	7548-7552	task	_
57-34	7553-7559	phases	_
57-35	7560-7561	.	_

58-1	7562-7564	In	_
58-2	7565-7568	the	_
58-3	7569-7576	current	_
58-4	7577-7584	project	_
58-5	7585-7586	,	_
58-6	7587-7589	we	_
58-7	7590-7599	collapsed	_
58-8	7600-7606	across	_
58-9	7607-7613	epochs	_
58-10	7614-7617	and	_
58-11	7618-7627	estimated	_
58-12	7628-7637	trialwise	_
58-13	7638-7649	hemodynamic	_
58-14	7650-7659	responses	_
58-15	7660-7662	to	_
58-16	7663-7667	gain	_
58-17	7668-7672	more	_
58-18	7673-7678	power	_
58-19	7679-7690	identifying	_
58-20	7691-7698	effects	_
58-21	7699-7701	of	_
58-22	7702-7710	interest	_
58-23	7711-7712	.	_

59-1	7713-7717	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
59-2	7718-7722	Data	_
59-3	7723-7734	Acquisition	_
59-4	7735-7738	and	_
59-5	7739-7752	Preprocessing	_
59-6	7753-7754	.	_

60-1	7755-7759	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-2	7760-7764	data	_
60-3	7765-7769	were	_
60-4	7770-7778	acquired	_
60-5	7779-7782	and	_
60-6	7783-7795	preprocessed	_
60-7	7796-7801	using	_
60-8	7802-7814	standardized	_
60-9	7815-7825	approaches	_
60-10	7826-7830	with	_
60-11	7831-7834	the	_
60-12	7835-7839	same	_
60-13	7840-7850	parameters	_
60-14	7851-7853	as	_
60-15	7854-7857	our	_
60-16	7858-7866	previous	_
60-17	7867-7871	work	_
60-18	7872-7873	(	_
60-19	7874-7877	see	_
60-20	7878-7888	Supplement	_
60-21	7889-7890	)	_
60-22	7891-7892	.	_

61-1	7893-7902	Cognitive	_
61-2	7903-7910	Battery	_
61-3	7911-7912	.	_

62-1	7913-7915	At	_
62-2	7916-7917	a	_
62-3	7918-7926	separate	_
62-4	7927-7932	visit	_
62-5	7933-7939	during	_
62-6	7940-7948	baseline	_
62-7	7949-7952	and	_
62-8	7953-7962	follow-up	_
62-9	7963-7968	years	_
62-10	7969-7970	,	_
62-11	7971-7983	participants	_
62-12	7984-7993	completed	_
62-13	7994-8002	multiple	_
62-14	8003-8012	cognitive	_
62-15	8013-8018	tests	_
62-16	8019-8020	,	_
62-17	8021-8030	including	_
62-18	8031-8032	a	_
62-19	8033-8041	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-20	8042-8054	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-21	8055-8060	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-22	8061-8064	for	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-23	8065-8076	Children-IV	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-24	8077-8089	intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-25	8090-8094	test	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-26	8095-8099	with	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-27	8100-8110	Perceptual	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-28	8111-8120	Reasoning	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-29	8121-8122	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-30	8123-8127	WISC	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-31	8128-8131	PER	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-32	8132-8133	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
62-33	8134-8135	,	_
62-34	8136-8146	Processing	_
62-35	8147-8152	Speed	_
62-36	8153-8154	,	_
62-37	8155-8161	Verbal	_
62-38	8162-8175	Comprehension	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
62-39	8176-8177	,	_
62-40	8178-8181	and	_
62-41	8182-8184	WM	_
62-42	8185-8194	subscales	_
62-43	8195-8196	,	_
62-44	8197-8200	and	_
62-45	8201-8204	the	_
62-46	8205-8214	following	_
62-47	8215-8226	assessments	_
62-48	8227-8231	from	_
62-49	8232-8235	the	_
62-50	8236-8245	Cambridge	_
62-51	8246-8264	Neuropsychological	_
62-52	8265-8269	Test	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
62-53	8270-8279	Automated	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
62-54	8280-8287	Battery	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
62-55	8288-8289	(	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
62-56	8290-8296	CANTAB	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
62-57	8297-8298	)	_
62-58	8299-8300	:	_
62-59	8301-8312	Intra-Extra	_
62-60	8313-8324	Dimensional	_
62-61	8325-8328	Set	_
62-62	8329-8334	Shift	_
62-63	8335-8336	,	_
62-64	8337-8340	One	_
62-65	8341-8346	Touch	_
62-66	8347-8356	Stockings	_
62-67	8357-8359	of	_
62-68	8360-8369	Cambridge	_
62-69	8370-8371	(	_
62-70	8372-8375	OTS	_
62-71	8376-8377	)	_
62-72	8378-8379	,	_
62-73	8380-8387	Spatial	_
62-74	8388-8392	Span	_
62-75	8393-8394	,	_
62-76	8395-8398	and	_
62-77	8399-8406	Spatial	_
62-78	8407-8409	WM	_
62-79	8410-8411	(	_
62-80	8412-8422	Supplement	_
62-81	8423-8424	)	_
62-82	8425-8426	.	_

63-1	8427-8438	Statistical	_
63-2	8439-8447	Analysis	_
63-3	8448-8457	Covariate	_
63-4	8458-8467	Selection	_
63-5	8468-8471	and	_
63-6	8472-8480	Analysis	_
63-7	8481-8482	.	_

64-1	8483-8488	Based	_
64-2	8489-8491	on	_
64-3	8492-8495	our	_
64-4	8496-8506	hypothesis	_
64-5	8507-8511	that	_
64-6	8512-8526	neurocognitive	_
64-7	8527-8538	differences	_
64-8	8539-8549	associated	_
64-9	8550-8554	with	_
64-10	8555-8563	cannabis	_
64-11	8564-8567	may	_
64-12	8568-8570	be	_
64-13	8571-8577	driven	_
64-14	8578-8580	by	_
64-15	8581-8584	SES	_
64-16	8585-8591	and/or	_
64-17	8592-8595	EXT	_
64-18	8596-8597	,	_
64-19	8598-8600	we	_
64-20	8601-8609	examined	_
64-21	8610-8615	their	_
64-22	8616-8627	association	_
64-23	8628-8632	with	_
64-24	8633-8636	all	_
64-25	8637-8651	neurocognitive	_
64-26	8652-8660	outcomes	_
64-27	8661-8662	.	_

65-1	8663-8665	In	_
65-2	8666-8671	cases	_
65-3	8672-8677	where	_
65-4	8678-8681	SES	_
65-5	8682-8684	or	_
65-6	8685-8688	EXT	_
65-7	8689-8692	had	_
65-8	8693-8694	a	_
65-9	8695-8706	significant	_
65-10	8707-8718	association	_
65-11	8719-8723	with	_
65-12	8724-8727	the	_
65-13	8728-8732	same	_
65-14	8733-8740	outcome	_
65-15	8741-8743	as	_
65-16	8744-8752	cannabis	_
65-17	8753-8756	use	_
65-18	8757-8758	,	_
65-19	8759-8761	we	_
65-20	8762-8766	used	_
65-21	8767-8776	mediation	_
65-22	8777-8785	analysis	_
65-23	8786-8787	[	_
65-24	8788-8797	bootstrap	_
65-25	8798-8807	procedure	_
65-26	8808-8812	with	_
65-27	8813-8817	5000	_
65-28	8818-8823	draws	_
65-29	8824-8825	]	_
65-30	8826-8828	to	_
65-31	8829-8842	dimensionally	_
65-32	8843-8849	assess	_
65-33	8850-8853	the	_
65-34	8854-8860	extent	_
65-35	8861-8863	to	_
65-36	8864-8869	which	_
65-37	8870-8873	SES	_
65-38	8874-8877	and	_
65-39	8878-8881	EXT	_
65-40	8882-8893	contributed	_
65-41	8894-8896	to	_
65-42	8897-8905	cannabis	_
65-43	8906-8911	group	_
65-44	8912-8923	differences	_
65-45	8924-8926	on	_
65-46	8927-8941	neurocognitive	_
65-47	8942-8950	outcomes	_
65-48	8951-8952	.	_

66-1	8953-8957	This	_
66-2	8958-8966	analysis	_
66-3	8967-8974	allowed	_
66-4	8975-8977	us	_
66-5	8978-8980	to	_
66-6	8981-8994	statistically	_
66-7	8995-8999	test	_
66-8	9000-9003	the	_
66-9	9004-9012	relative	_
66-10	9013-9025	contribution	_
66-11	9026-9028	of	_
66-12	9029-9032	SES	_
66-13	9033-9036	and	_
66-14	9037-9040	EXT	_
66-15	9041-9043	to	_
66-16	9044-9052	observed	_
66-17	9053-9061	cannabis	_
66-18	9062-9076	neurocognitive	_
66-19	9077-9088	differences	_
66-20	9089-9090	,	_
66-21	9091-9093	as	_
66-22	9094-9101	opposed	_
66-23	9102-9104	to	_
66-24	9105-9111	solely	_
66-25	9112-9119	relying	_
66-26	9120-9122	on	_
66-27	9123-9126	the	_
66-28	9127-9141	interpretation	_
66-29	9142-9144	of	_
66-30	9145-9157	significance	_
66-31	9158-9162	with	_
66-32	9163-9166	and	_
66-33	9167-9174	without	_
66-34	9175-9180	these	_
66-35	9181-9190	variables	_
66-36	9191-9193	as	_
66-37	9194-9204	covariates	_
66-38	9205-9206	.	_

67-1	9207-9215	Cannabis	_
67-2	9216-9226	initiators	_
67-3	9227-9231	were	_
67-4	9232-9236	also	_
67-5	9237-9241	more	_
67-6	9242-9248	likely	_
67-7	9249-9251	to	_
67-8	9252-9260	initiate	_
67-9	9261-9268	alcohol	_
67-10	9269-9272	use	_
67-11	9273-9274	(	_
67-12	9275-9280	Table	_
67-13	9281-9282	1	_
67-14	9283-9284	)	_
67-15	9285-9286	,	_
67-16	9287-9290	and	_
67-17	9291-9300	therefore	_
67-18	9301-9303	we	_
67-19	9304-9308	used	_
67-20	9309-9316	alcohol	_
67-21	9317-9322	usage	_
67-22	9323-9328	group	_
67-23	9329-9331	as	_
67-24	9332-9333	a	_
67-25	9334-9343	covariate	_
67-26	9344-9347	and	_
67-27	9348-9357	moderator	_
67-28	9358-9360	to	_
67-29	9361-9368	examine	_
67-30	9369-9372	the	_
67-31	9373-9384	specificity	_
67-32	9385-9387	of	_
67-33	9388-9395	results	_
67-34	9396-9397	.	_

68-1	9398-9405	Scanner	_
68-2	9406-9408	WM	_
68-3	9409-9420	Performance	_
68-4	9421-9422	.	_

69-1	9423-9425	WM	_
69-2	9426-9434	accuracy	_
69-3	9435-9438	and	_
69-4	9439-9447	reaction	_
69-5	9448-9452	time	_
69-6	9453-9456	for	_
69-7	9457-9464	correct	_
69-8	9465-9471	trials	_
69-9	9472-9476	were	_
69-10	9477-9485	analyzed	_
69-11	9486-9490	with	_
69-12	9491-9497	linear	_
69-13	9498-9511	mixed-effects	_
69-14	9512-9518	models	_
69-15	9519-9520	[	_
69-16	9521-9525	lme4	_
69-17	9526-9533	package	_
69-18	9534-9535	]	_
69-19	9536-9537	.	_

70-1	9538-9546	Accuracy	_
70-2	9547-9555	analysis	_
70-3	9556-9564	excluded	_
70-4	9565-9571	trials	_
70-5	9572-9576	with	_
70-6	9577-9585	omission	_
70-7	9586-9592	errors	_
70-8	9593-9594	(	_
70-9	9595-9602	details	_
70-10	9603-9605	on	_
70-11	9606-9611	model	_
70-12	9612-9625	specification	_
70-13	9626-9629	can	_
70-14	9630-9632	be	_
70-15	9633-9638	found	_
70-16	9639-9641	in	_
70-17	9642-9645	the	_
70-18	9646-9656	Supplement	_
70-19	9657-9658	)	_
70-20	9659-9660	.	_

71-1	9661-9668	Primary	_
71-2	9669-9677	analyses	_
71-3	9678-9685	focused	_
71-4	9686-9688	on	_
71-5	9689-9692	the	_
71-6	9693-9697	main	_
71-7	9698-9705	effects	_
71-8	9706-9708	of	_
71-9	9709-9714	usage	_
71-10	9715-9720	group	_
71-11	9721-9724	and	_
71-12	9725-9737	interactions	_
71-13	9738-9742	with	_
71-14	9743-9748	visit	_
71-15	9749-9750	(	_
71-16	9751-9769	baseline/follow-up	_
71-17	9770-9771	)	_
71-18	9772-9773	.	_

72-1	9774-9786	Interactions	_
72-2	9787-9794	between	_
72-3	9795-9799	task	_
72-4	9800-9807	factors	_
72-5	9808-9811	and	_
72-6	9812-9817	usage	_
72-7	9818-9823	group	_
72-8	9824-9828	were	_
72-9	9829-9836	largely	_
72-10	9837-9851	nonsignificant	_
72-11	9852-9853	(	_
72-12	9854-9864	Supplement	_
72-13	9865-9866	)	_
72-14	9867-9868	.	_

73-1	9869-9873	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
73-2	9874-9875	.	_

74-1	9876-9879	For	_
74-2	9880-9884	each	_
74-3	9885-9896	participant	_
74-4	9897-9898	,	_
74-5	9899-9901	at	_
74-6	9902-9906	each	_
74-7	9907-9912	visit	_
74-8	9913-9914	,	_
74-9	9915-9924	trialwise	_
74-10	9925-9929	BOLD	_
74-11	9930-9939	responses	_
74-12	9940-9944	were	_
74-13	9945-9954	estimated	_
74-14	9955-9960	using	_
74-15	9961-9965	AFNI	_
74-16	9966-9967	’	_
74-17	9968-9969	s	_
74-18	9970-9982	3dDeconvolve	_
74-19	9983-9984	.	_

75-1	9985-9990	Trial	_
75-2	9991-9995	time	_
75-3	9996-10003	courses	_
75-4	10004-10007	for	_
75-5	10008-10015	correct	_
75-6	10016-10017	,	_
75-7	10018-10027	incorrect	_
75-8	10028-10029	,	_
75-9	10030-10033	and	_
75-10	10034-10041	partial	_
75-11	10042-10048	trials	_
75-12	10049-10053	were	_
75-13	10054-10061	modeled	_
75-14	10062-10067	using	_
75-15	10068-10072	TENT	_
75-16	10073-10078	basis	_
75-17	10079-10088	functions	_
75-18	10089-10097	spanning	_
75-19	10098-10100	28	_
75-20	10101-10108	seconds	_
75-21	10109-10113	with	_
75-22	10114-10116	15	_
75-23	10117-10121	time	_
75-24	10122-10127	steps	_
75-25	10128-10129	(	_
75-26	10130-10133	TRs	_
75-27	10134-10135	)	_
75-28	10136-10137	.	_

76-1	10138-10143	Owing	_
76-2	10144-10146	to	_
76-3	10147-10150	the	_
76-4	10151-10159	temporal	_
76-5	10160-10170	properties	_
76-6	10171-10173	of	_
76-7	10174-10185	hemodynamic	_
76-8	10186-10195	responses	_
76-9	10196-10197	,	_
76-10	10198-10203	1500-	_
76-11	10204-10207	and	_
76-12	10208-10215	6000-ms	_
76-13	10216-10221	delay	_
76-14	10222-10228	trials	_
76-15	10229-10233	were	_
76-16	10234-10241	modeled	_
76-17	10242-10252	separately	_
76-18	10253-10254	.	_

77-1	10255-10265	Additional	_
77-2	10266-10274	nuisance	_
77-3	10275-10285	regressors	_
77-4	10286-10294	included	_
77-5	10295-10298	six	_
77-6	10299-10309	rigid-body	_
77-7	10310-10314	head	_
77-8	10315-10321	motion	_
77-9	10322-10332	parameters	_
77-10	10333-10336	and	_
77-11	10337-10342	their	_
77-12	10343-10354	derivatives	_
77-13	10355-10356	,	_
77-14	10357-10360	and	_
77-15	10361-10368	runwise	_
77-16	10369-10373	zero	_
77-17	10374-10381	through	_
77-18	10382-10387	third	_
77-19	10388-10393	order	_
77-20	10394-10405	polynomials	_
77-21	10406-10407	.	_

78-1	10408-10411	The	_
78-2	10412-10419	current	_
78-3	10420-10423	and	_
78-4	10424-10433	preceding	_
78-5	10434-10437	TRs	_
78-6	10438-10442	were	_
78-7	10443-10451	censored	_
78-8	10452-10454	if	_
78-9	10455-10458	the	_
78-10	10459-10468	Euclidean	_
78-11	10469-10473	norm	_
78-12	10474-10478	head	_
78-13	10479-10485	motion	_
78-14	10486-10494	distance	_
78-15	10495-10504	surpassed	_
78-16	10505-10508	0.9	_
78-17	10509-10511	mm	_
78-18	10512-10513	(	_
78-19	10514-10524	percentage	_
78-20	10525-10527	of	_
78-21	10528-10531	TRs	_
78-22	10532-10540	censored	_
78-23	10541-10542	:	_
78-24	10543-10547	mean	_
78-25	10548-10549	6	_
78-26	10550-10557	SD,3.18	_
78-27	10558-10559	%	_
78-28	10560-10561	±	_
78-29	10562-10566	6.29	_
78-30	10567-10568	%	_
78-31	10569-10570	)	_
78-32	10571-10572	.	_

79-1	10573-10577	fMRI	_
79-2	10578-10579	:	_
79-3	10580-10589	Voxelwise	_
79-4	10590-10597	Testing	_
79-5	10598-10599	.	_

80-1	10600-10607	Primary	_
80-2	10608-10616	analysis	_
80-3	10617-10626	consisted	_
80-4	10627-10629	of	_
80-5	10630-10635	three	_
80-6	10636-10645	voxelwise	_
80-7	10646-10654	analyses	_
80-8	10655-10656	(	_
80-9	10657-10665	baseline	_
80-10	10666-10667	,	_
80-11	10668-10677	follow-up	_
80-12	10678-10679	,	_
80-13	10680-10683	and	_
80-14	10684-10687	the	_
80-15	10688-10699	interaction	_
80-16	10700-10707	between	_
80-17	10708-10714	visits	_
80-18	10715-10716	)	_
80-19	10717-10718	.	_

81-1	10719-10728	Voxelwise	_
81-2	10729-10734	group	_
81-3	10735-10742	effects	_
81-4	10743-10747	were	_
81-5	10748-10756	examined	_
81-6	10757-10759	on	_
81-7	10760-10764	time	_
81-8	10765-10772	courses	_
81-9	10773-10777	from	_
81-10	10778-10785	correct	_
81-11	10786-10792	trials	_
81-12	10793-10800	entered	_
81-13	10801-10805	into	_
81-14	10806-10807	a	_
81-15	10808-10817	voxelwise	_
81-16	10818-10830	multivariate	_
81-17	10831-10836	model	_
81-18	10837-10838	[	_
81-19	10839-10844	3dMVM	_
81-20	10845-10846	]	_
81-21	10847-10848	.	_

82-1	10849-10860	Interaction	_
82-2	10861-10866	terms	_
82-3	10867-10874	between	_
82-4	10875-10877	TR	_
82-5	10878-10881	and	_
82-6	10882-10890	cannabis	_
82-7	10891-10896	group	_
82-8	10897-10899	or	_
82-9	10900-10905	among	_
82-10	10906-10908	TR	_
82-11	10909-10910	,	_
82-12	10911-10919	cannabis	_
82-13	10920-10925	group	_
82-14	10926-10927	,	_
82-15	10928-10931	and	_
82-16	10932-10937	visit	_
82-17	10938-10942	were	_
82-18	10943-10947	used	_
82-19	10948-10950	to	_
82-20	10951-10959	identify	_
82-21	10960-10966	voxels	_
82-22	10967-10972	whose	_
82-23	10973-10984	hemodynamic	_
82-24	10985-10993	response	_
82-25	10994-11002	function	_
82-26	11003-11011	differed	_
82-27	11012-11019	between	_
82-28	11020-11026	groups	_
82-29	11027-11029	at	_
82-30	11030-11033	one	_
82-31	11034-11039	visit	_
82-32	11040-11042	or	_
82-33	11043-11050	between	_
82-34	11051-11057	visits	_
82-35	11058-11059	,	_
82-36	11060-11072	respectively	_
82-37	11073-11074	.	_

83-1	11075-11084	Voxelwise	_
83-2	11085-11096	differences	_
83-3	11097-11101	were	_
83-4	11102-11113	constrained	_
83-5	11114-11116	to	_
83-6	11117-11124	include	_
83-7	11125-11131	voxels	_
83-8	11132-11136	with	_
83-9	11137-11138	1	_
83-10	11139-11140	)	_
83-11	11141-11144	≥50	_
83-12	11145-11146	%	_
83-13	11147-11158	probability	_
83-14	11159-11161	of	_
83-15	11162-11167	being	_
83-16	11168-11172	gray	_
83-17	11173-11179	matter	_
83-18	11180-11182	in	_
83-19	11183-11186	the	_
83-20	11187-11195	Montreal	_
83-21	11196-11208	Neurological	_
83-22	11209-11222	Institute-152	_
83-23	11223-11231	template	_
83-24	11232-11233	,	_
83-25	11234-11235	2	_
83-26	11236-11237	)	_
83-27	11238-11242	full	_
83-28	11243-11254	echo-planar	_
83-29	11255-11262	imaging	_
83-30	11263-11271	coverage	_
83-31	11272-11274	in	_
83-32	11275-11278	all	_
83-33	11279-11291	participants	_
83-34	11292-11293	,	_
83-35	11294-11297	and	_
83-36	11298-11299	3	_
83-37	11300-11301	)	_
83-38	11302-11303	a	_
83-39	11304-11308	main	_
83-40	11309-11315	effect	_
83-41	11316-11318	of	_
83-42	11319-11321	TR	_
83-43	11322-11323	(	_
83-44	11324-11325	F	_
83-45	11326-11330	test	_
83-46	11331-11332	)	_
83-47	11333-11335	of	_
83-48	11336-11337	p	_
83-49	11338-11339	<	_
83-50	11340-11344	.005	_
83-51	11345-11346	(	_
83-52	11347-11358	uncorrected	_
83-53	11359-11360	)	_
83-54	11361-11362	(	_
83-55	11363-11375	Supplemental	_
83-56	11376-11382	Figure	_
83-57	11383-11385	S3	_
83-58	11386-11387	)	_
83-59	11388-11389	.	_

84-1	11390-11399	Resulting	_
84-2	11400-11408	clusters	_
84-3	11409-11413	were	_
84-4	11414-11420	deemed	_
84-5	11421-11423	to	_
84-6	11424-11428	have	_
84-7	11429-11438	corrected	_
84-8	11439-11451	significance	_
84-9	11452-11454	if	_
84-10	11455-11458	all	_
84-11	11459-11465	voxels	_
84-12	11466-11472	within	_
84-13	11473-11474	a	_
84-14	11475-11482	cluster	_
84-15	11483-11486	had	_
84-16	11487-11493	single	_
84-17	11494-11503	voxelwise	_
84-18	11504-11505	p	_
84-19	11506-11512	values	_
84-20	11513-11517	that	_
84-21	11518-11522	were	_
84-22	11523-11528	false	_
84-23	11529-11538	discovery	_
84-24	11539-11543	rate	_
84-25	11544-11545	(	_
84-26	11546-11549	FDR	_
84-27	11550-11551	)	_
84-28	11552-11562	-corrected	_
84-29	11563-11574	significant	_
84-30	11575-11576	(	_
84-31	11577-11578	q	_
84-32	11579-11580	<	_
84-33	11581-11584	.05	_
84-34	11585-11586	)	_
84-35	11587-11590	and	_
84-36	11591-11594	the	_
84-37	11595-11602	cluster	_
84-38	11603-11607	size	_
84-39	11608-11616	exceeded	_
84-40	11617-11620	the	_
84-41	11621-11627	number	_
84-42	11628-11630	of	_
84-43	11631-11637	voxels	_
84-44	11638-11646	required	_
84-45	11647-11650	for	_
84-46	11651-11652	a	_
84-47	11653-11664	significant	_
84-48	11665-11672	cluster	_
84-49	11673-11677	size	_
84-50	11678-11679	,	_
84-51	11680-11689	according	_
84-52	11690-11692	to	_
84-53	11693-11697	AFNI	_
84-54	11698-11699	’	_
84-55	11700-11701	s	_
84-56	11702-11712	3dClustsim	_
84-57	11713-11714	(	_
84-58	11715-11718	acf	_
84-59	11719-11725	option	_
84-60	11726-11727	)	_
84-61	11728-11729	.	_

85-1	11730-11735	Based	_
85-2	11736-11738	on	_
85-3	11739-11743	this	_
85-4	11744-11752	analysis	_
85-5	11753-11754	,	_
85-6	11755-11757	11	_
85-7	11758-11760	or	_
85-8	11761-11765	more	_
85-9	11766-11776	contiguous	_
85-10	11777-11778	(	_
85-11	11779-11793	faces-touching	_
85-12	11794-11795	;	_
85-13	11796-11800	AFNI	_
85-14	11801-11804	NN1	_
85-15	11805-11806	)	_
85-16	11807-11813	voxels	_
85-17	11814-11818	with	_
85-18	11819-11820	a	_
85-19	11821-11827	single	_
85-20	11828-11837	voxelwise	_
85-21	11838-11847	threshold	_
85-22	11848-11850	of	_
85-23	11851-11852	q	_
85-24	11853-11854	<	_
85-25	11855-11858	.05	_
85-26	11859-11860	(	_
85-27	11861-11869	baseline	_
85-28	11870-11871	p	_
85-29	11872-11873	=	_
85-30	11874-11879	.0013	_
85-31	11880-11881	,	_
85-32	11882-11891	follow-up	_
85-33	11892-11893	p	_
85-34	11894-11895	=	_
85-35	11896-11901	.0007	_
85-36	11902-11903	,	_
85-37	11904-11909	group	_
85-38	11910-11912	by	_
85-39	11913-11918	visit	_
85-40	11919-11930	interaction	_
85-41	11931-11932	p	_
85-42	11933-11934	=	_
85-43	11935-11940	.0002	_
85-44	11941-11942	,	_
85-45	11943-11947	main	_
85-46	11948-11954	effect	_
85-47	11955-11957	of	_
85-48	11958-11963	usage	_
85-49	11964-11969	group	_
85-50	11970-11976	across	_
85-51	11977-11983	visits	_
85-52	11984-11985	p	_
85-53	11986-11987	=	_
85-54	11988-11993	.0015	_
85-55	11994-11995	)	_
85-56	11996-12000	were	_
85-57	12001-12005	used	_
85-58	12006-12008	to	_
85-59	12009-12015	define	_
85-60	12016-12027	significant	_
85-61	12028-12036	clusters	_
85-62	12037-12038	(	_
85-63	12039-12049	Supplement	_
85-64	12050-12051	)	_
85-65	12052-12053	.	_

86-1	12054-12058	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
86-2	12059-12060	:	_
86-3	12061-12070	Covariate	_
86-4	12071-12074	and	_
86-5	12075-12089	Brain-Behavior	_
86-6	12090-12098	Analysis	_
86-7	12099-12100	.	_

87-1	12101-12110	Covariate	_
87-2	12111-12119	analysis	_
87-3	12120-12124	used	_
87-4	12125-12131	robust	_
87-5	12132-12138	linear	_
87-6	12139-12149	regression	_
87-7	12150-12151	(	_
87-8	12152-12164	m-estimation	_
87-9	12165-12166	)	_
87-10	12167-12176	performed	_
87-11	12177-12179	on	_
87-12	12180-12190	individual	_
87-13	12191-12202	participant	_
87-14	12203-12212	estimates	_
87-15	12213-12215	of	_
87-16	12216-12225	trialwise	_
87-17	12226-12230	BOLD	_
87-18	12231-12240	responses	_
87-19	12241-12242	,	_
87-20	12243-12251	measured	_
87-21	12252-12254	as	_
87-22	12255-12258	the	_
87-23	12259-12262	dot	_
87-24	12263-12270	product	_
87-25	12271-12273	of	_
87-26	12274-12277	the	_
87-27	12278-12289	participant	_
87-28	12290-12294	time	_
87-29	12295-12301	course	_
87-30	12302-12305	and	_
87-31	12306-12309	the	_
87-32	12310-12315	grand	_
87-33	12316-12320	mean	_
87-34	12321-12325	time	_
87-35	12326-12332	course	_
87-36	12333-12334	.	_

88-1	12335-12339	This	_
88-2	12340-12348	approach	_
88-3	12349-12357	resulted	_
88-4	12358-12360	in	_
88-5	12361-12362	a	_
88-6	12363-12369	single	_
88-7	12370-12378	estimate	_
88-8	12379-12381	of	_
88-9	12382-12391	trialwise	_
88-10	12392-12396	BOLD	_
88-11	12397-12407	expression	_
88-12	12408-12413	while	_
88-13	12414-12418	also	_
88-14	12419-12432	accommodating	_
88-15	12433-12437	both	_
88-16	12438-12442	long	_
88-17	12443-12446	and	_
88-18	12447-12452	short	_
88-19	12453-12458	delay	_
88-20	12459-12465	trials	_
88-21	12466-12467	’	_
88-22	12468-12479	hemodynamic	_
88-23	12480-12488	response	_
88-24	12489-12497	function	_
88-25	12498-12503	shape	_
88-26	12504-12505	.	_

89-1	12506-12518	Significance	_
89-2	12519-12525	values	_
89-3	12526-12530	were	_
89-4	12531-12534	FDR	_
89-5	12535-12544	corrected	_
89-6	12545-12551	across	_
89-7	12552-12560	clusters	_
89-8	12561-12564	for	_
89-9	12565-12569	each	_
89-10	12570-12577	measure	_
89-11	12578-12579	.	_

90-1	12580-12582	To	_
90-2	12583-12589	assist	_
90-3	12590-12592	in	_
90-4	12593-12596	the	_
90-5	12597-12611	interpretation	_
90-6	12612-12614	of	_
90-7	12615-12619	BOLD	_
90-8	12620-12630	activation	_
90-9	12631-12638	effects	_
90-10	12639-12640	,	_
90-11	12641-12643	we	_
90-12	12644-12651	present	_
90-13	12652-12655	the	_
90-14	12656-12667	association	_
90-15	12668-12670	of	_
90-16	12671-12681	individual	_
90-17	12682-12686	BOLD	_
90-18	12687-12697	activation	_
90-19	12698-12701	dot	_
90-20	12702-12710	products	_
90-21	12711-12714	and	_
90-22	12715-12717	WM	_
90-23	12718-12726	accuracy	_
90-24	12727-12730	for	_
90-25	12731-12734	all	_
90-26	12735-12743	clusters	_
90-27	12744-12745	.	_

91-1	12746-12748	In	_
91-2	12749-12754	cases	_
91-3	12755-12760	where	_
91-4	12761-12766	there	_
91-5	12767-12770	was	_
91-6	12771-12772	a	_
91-7	12773-12784	significant	_
91-8	12785-12786	(	_
91-9	12787-12800	FDR-corrected	_
91-10	12801-12802	)	_
91-11	12803-12814	association	_
91-12	12815-12816	,	_
91-13	12817-12826	mediation	_
91-14	12827-12835	analysis	_
91-15	12836-12839	was	_
91-16	12840-12849	performed	_
91-17	12850-12852	to	_
91-18	12853-12860	examine	_
91-19	12861-12868	whether	_
91-20	12869-12880	participant	_
91-21	12881-12885	BOLD	_
91-22	12886-12894	response	_
91-23	12895-12898	may	_
91-24	12899-12906	account	_
91-25	12907-12910	for	_
91-26	12911-12916	group	_
91-27	12917-12928	differences	_
91-28	12929-12931	in	_
91-29	12932-12934	WM	_
91-30	12935-12946	performance	_
91-31	12947-12948	.	_

92-1	12949-12961	Significance	_
92-2	12962-12968	values	_
92-3	12969-12972	for	_
92-4	12973-12981	indirect	_
92-5	12982-12989	effects	_
92-6	12990-12994	were	_
92-7	12995-13003	obtained	_
92-8	13004-13009	using	_
92-9	13010-13014	5000	_
92-10	13015-13020	draws	_
92-11	13021-13023	in	_
92-12	13024-13025	a	_
92-13	13026-13035	bootstrap	_
92-14	13036-13045	procedure	_
92-15	13046-13047	[	_
92-16	13048-13057	mediation	_
92-17	13058-13065	package	_
92-18	13066-13067	]	_
92-19	13068-13069	.	_

93-1	13070-13079	Cognitive	_
93-2	13080-13087	Battery	_
93-3	13088-13089	.	_

94-1	13090-13095	Group	_
94-2	13096-13107	differences	_
94-3	13108-13110	on	_
94-4	13111-13114	the	_
94-5	13115-13124	cognitive	_
94-6	13125-13132	battery	_
94-7	13133-13137	were	_
94-8	13138-13146	analyzed	_
94-9	13147-13152	using	_
94-10	13153-13158	Welch	_
94-11	13159-13160	’	_
94-12	13161-13162	s	_
94-13	13163-13170	unequal	_
94-14	13171-13179	variance	_
94-15	13180-13181	t	_
94-16	13182-13187	tests	_
94-17	13188-13189	.	_

95-1	13190-13196	Effect	_
95-2	13197-13202	sizes	_
95-3	13203-13204	(	_
95-4	13205-13210	Cohen	_
95-5	13211-13212	’	_
95-6	13213-13214	s	_
95-7	13215-13216	d	_
95-8	13217-13218	)	_
95-9	13219-13222	and	_
95-10	13223-13228	their	_
95-11	13229-13231	95	_
95-12	13232-13233	%	_
95-13	13234-13244	confidence	_
95-14	13245-13254	intervals	_
95-15	13255-13256	(	_
95-16	13257-13260	CIs	_
95-17	13261-13262	)	_
95-18	13263-13267	were	_
95-19	13268-13277	estimated	_
95-20	13278-13282	with	_
95-21	13283-13286	the	_
95-22	13287-13294	effsize	_
95-23	13295-13302	package	_
95-24	13303-13305	in	_
95-25	13306-13308	R.	_
95-26	13309-13318	Secondary	_
95-27	13319-13325	models	_
95-28	13326-13334	included	_
95-29	13335-13338	SES	_
95-30	13339-13340	,	_
95-31	13341-13344	EXT	_
95-32	13345-13346	,	_
95-33	13347-13350	and	_
95-34	13351-13358	alcohol	_
95-35	13359-13364	usage	_
95-36	13365-13367	as	_
95-37	13368-13378	covariates	_
95-38	13379-13382	and	_
95-39	13383-13387	used	_
95-40	13388-13394	robust	_
95-41	13395-13401	linear	_
95-42	13402-13412	regression	_
95-43	13413-13414	(	_
95-44	13415-13427	m-estimation	_
95-45	13428-13429	)	_
95-46	13430-13433	and	_
95-47	13434-13438	Wald	_
95-48	13439-13440	’	_
95-49	13441-13442	s	_
95-50	13443-13447	test	_
95-51	13448-13451	for	_
95-52	13452-13464	significance	_
95-53	13465-13466	(	_
95-54	13467-13480	FDR-corrected	_
95-55	13481-13487	within	_
95-56	13488-13492	each	_
95-57	13493-13499	family	_
95-58	13500-13502	of	_
95-59	13503-13508	tests	_
95-60	13509-13510	:	_
95-61	13511-13519	baseline	_
95-62	13520-13521	,	_
95-63	13522-13531	follow-up	_
95-64	13532-13533	,	_
95-65	13534-13537	and	_
95-66	13538-13548	difference	_
95-67	13549-13555	scores	_
95-68	13556-13557	)	_
95-69	13558-13559	.	_

